Search results
Results from the WOW.Com Content Network
Quinidine is an antiarrhythmic drug that may reduce the chance of serious abnormal heart rhythms occurring in some people with Brugada syndrome. [10] [45] It is most frequently used in people with Brugada syndrome who have an ICD and have experienced several episodes of life-threatening arrhythmias, but may also be used in people at high risk ...
The most typical form of APVS is a tetralogy of Fallot variant, [4] however, case studies have linked APVS to several different congenital cardiac syndromes, such as agenesis of ductus arteriosus, [5] persistent ductus arteriosus, [6] atrioventricular septal defect, [7] pulmonary branching abnormalities, [8] [9] transposition of the great arteries, [10] and type B interrupted aortic arch. [11]
Long QT syndrome, the most common form of cardiac channelopathy, is characterized by prolonged ventricular repolarization, predisposing to a high risk of ventricular tachyarrhythmias (e.g., torsade de pointes), syncope, and sudden cardiac death.
Brugada syndrome; Brunner syndrome; Budd–Chiari syndrome; Burning feet syndrome; Burning mouth syndrome; Burnside–Butler syndrome; Buschke–Ollendorff syndrome; Bálint's syndrome; Börjeson-Forssman-Lehmann syndrome
Long QT syndrome, Brugada syndrome, Andersen-Tawil syndrome, Early repolarization syndrome: Treatment: Avoidance of strenuous exercise, medication, implantable cardioverter defibrillator [2] Medication: Beta-adrenoceptor blockers, Verapamil, Flecainide [2] Prognosis: 13–20% life threatening arrhythmias over 7–8 years [3] Frequency: 1:10,000 [4]
There is no cure for Brugada syndrome, but the condition may be treated using an implantable cardioverter defibrillator (ICD). [3] Medications to help control the abnormal heart rhythms include isoproterenol in those who are acutely unstable, and quinidine. [4] The family members of a patient with Brugada syndrome may require testing for the ...
This strong market position generates substantial cash flows that support shareholder returns. Turning to the specifics, the pharmaceutical giant offers investors a 4.3% dividend yield backed by a ...
Brugada syndrome is a genetic disease that can result in mutations in the sodium ion channel (gene SCN5A) of the myocytes in the heart. [10] Brugada syndrome can result in ventricular fibrillation and potentially death. It is a major cause of sudden unexpected cardiac death in young, otherwise healthy people. [11]